Unexplored therapeutic opportunities in the human genome. Read more about Unexplored therapeutic opportunities in the human genome.
Marked for death: targeting epigenetic changes in cancer. Read more about Marked for death: targeting epigenetic changes in cancer.
Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. Read more about Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Read more about Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.
Tackling reproducibility in academic preclinical drug discovery. Read more about Tackling reproducibility in academic preclinical drug discovery.
SLC transporters as therapeutic targets: emerging opportunities. Read more about SLC transporters as therapeutic targets: emerging opportunities.
Bringing together the academic drug discovery community. Read more about Bringing together the academic drug discovery community.
Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Read more about Tankyrase-targeted therapeutics: expanding opportunities in the PARP family.
Targeting the TGFβ signalling pathway in disease. Read more about Targeting the TGFβ signalling pathway in disease.
